目的 探討醒腦靜注射液聯(lián)合依達(dá)拉奉治療急性腦梗死的臨床療效。方法 選取2020年2月-2021年2月新鄭市人民醫(yī)院收治的98例急性腦梗死患者，按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各49例。對(duì)照組患者靜脈滴注依達(dá)拉奉注射液，將30 mg加入到0.9%氯化鈉注射液100 mL，2次/d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注醒腦靜注射液，20 mL加入到5%葡萄糖注射液250 mL，1次/d。兩組均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組相關(guān)評(píng)分、血清學(xué)指標(biāo)和血清炎性因子水平的變化情況。結(jié)果 治療后，治療組總有效率是98.0%，顯著高于對(duì)照組的75.5%（P<0.05）。治療后，兩組NIHSS評(píng)分均顯著降低，但GCS評(píng)分升高（P<0.05）；治療后，治療組NIHSS評(píng)分低于對(duì)照組，而GCS評(píng)分高于對(duì)照組（P<0.05）。治療后，兩組神經(jīng)特異性蛋白100β（S100β）、神經(jīng)元特異性烯醇化酶（NSE）水平均顯著降低，但腦源性神經(jīng)營(yíng)養(yǎng)因子（BDNF）水平顯著升高（P<0.05）；治療后，治療組血清學(xué)指標(biāo)改善優(yōu)于對(duì)照組（P<0.05）。治療后，兩組超敏C-反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-6（IL-6）及白細(xì)胞介素-1（IL-1β）水平均較治療前顯著降低（P<0.05）；治療后，治療組血清炎性因子低于對(duì)照組（P<0.05）。結(jié)論 醒腦靜注射液聯(lián)合依達(dá)拉奉治療急性腦梗死效果明顯，可有效降低機(jī)體炎性因子水平，改善腦血管功能，具有較高的安全性，值得臨床推廣應(yīng)用。

Objective To investigate the clinical effect of Xingnaojing Injection combined with edaravone in treatment of acute cerebral infarction. Methods A total of 98 patients with acute cerebral infarction admitted to Xinzheng People's Hospital from February 2020 to February 2021 were selected and divided into control group and treatment group according to random number table method, with 49 cases in each group. Patients in the control group were iv administered with Edaravone Injection, 30 mg was added to 0.9% sodium chloride injection 100 mL, twice daily. Patients in the treatment group were iv administered with Xingnaojing Injection on the basis of the control group, 20 mL was added to 5% glucose injection 250 mL, once daily. Both groups were treated for 14 d. The clinical efficacy of the two groups were observed, and the changes of related scores, serological indexes and serum inflammatory factors were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 98.0%, significantly higher than that of the control group (75.5%) (P<0.05). After treatment, NIHSS score was significantly decreased in both groups, but GCS score was increased (P<0.05). After treatment, NIHSS score in the treatment group was lower than that in the control group, while GCS score was higher than that in the control group (P<0.05). After treatment, the levels of neurospecific protein 100β (S100β) and neuron specific enolase (NSE) were significantly decreased, but the level of brain-derived neurotrophic factor (BDNF) was significantly increased in both groups (P<0.05). After treatment, serological indexes in the treatment group were better than those in the control group (P<0.05). After treatment, the levels of hypersensitive C-reactive protein (HS-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1β) in two groups were significantly decreased compared with before treatment (P<0.05). After treatment, the serum inflammatory factors in the treatment group were lower than those in the control group (P<0.05). Conclusion Xingnaojing Injection combined with edaravone has obvious effect in treatment of acute cerebral infarction, and can effectively reduce the body inflammatory factor levels, and can improve cerebrovascular function with high safety, which is worthy of clinical application.

R971